OBJECTIVES: To investigate the clinical and pathologic characteristics of patients with bone metastases identified at the time of newly diagnosed prostate carcinoma at biopsy. METHODS: From November 2002 to May 2004, 1587 consecutive patients had a pathologic diagnosis of prostate cancer and underwent conventional technetium-99m methylene diphosphonate scintigraphy of the entire body. The clinical and pathologic features of those patients with positive bone scan findings (group 1) were compared with those of a subcohort of 372 patients with negative bone scan findings performed at the same nuclear medicine department (group 2). RESULTS: A retrospective complete data collection was available for 1242 of 1587 patients. Bone metastases were found in 31 patients (2.5%). As expected, patients with skeletal metastases had a significantly greater mean serum total prostate-specific antigen level, and a Gleason sum of 8 or 9 was significantly more frequent in the pathologic findings of these subjects. Group 1 patients had a significantly greater prevalence of previous nonprostate primary neoplasms (chi-square 12.74, df = 1, P = 0.0004) and reported a greater prevalence of current use of H2 blockers for the treatment and prevention of gastroesophageal reflux disorders (chi-square 37.52, df = 1, P < 0.0001) than did group 2 patients. CONCLUSIONS: Our data have confirmed that bone metastases are more frequent in patients with high prostate-specific antigen levels and poorly differentiated tumors at biopsy regardless of the patient's age. A history of previous nonprostate primary neoplasms and the use of H2 blockers seemed to be more prevalent in those patients with bone metastases at diagnosis. PMID:16904453[PubMed - indexed for MEDLINE] MeSH Terms, SubstancesMeSH TermsAgedBone Neoplasms/radionuclide imaging*Bone Neoplasms/secondary*HumansMaleProstatic Neoplasms/pathology*Radiopharmaceuticals/diagnostic useRetrospective StudiesTechnetium Tc 99m Medronate/diagnostic useSubstancesRadiopharmaceuticalsTechnetium Tc 99m Medronate LinkOut - more resourcesFull Text SourcesElsevier ScienceEBSCOMD ConsultOhioLINK Electronic Journal CenterSwets Information ServicesOther Literature SourcesLabome Researcher Resource - ExactAntigen/LabomeMedicalProstate Cancer - MedlinePlus Health InformationBone Cancer - MedlinePlus Health Information • Supplemental Content Related citations [Comparison of serum prostate specific antigen levels and bone scintigraphy in patients with prostate carcinoma]. [Medicina (Kaunas). 2003] [Comparison of serum prostate specific antigen levels and bone scintigraphy in patients with prostate carcinoma]. Bielickaite J, Zadeikaite R, Jurkiene N, Kiudelis J, Kuprionis G. Medicina (Kaunas). 2003; 39(9):867-71. The relationship between the serum prostate specific antigen and whole body scintigraphy in prostate cancer patients after prostatectomy. [Med Arh. 2006] The relationship between the serum prostate specific antigen and whole body scintigraphy in prostate cancer patients after prostatectomy. Begic A, Kucukalic-Selimovic E, Obralic N, Duric O, Lacevic N, Begovic-Hadzimuratovic S, Skopljak A, Dzubur-Aganovic M. Med Arh. 2006; 60(1):54-5. Prediction of radionuclide bone imaging findings by Gleason histologic grading of prostate carcinoma. [Clin Nucl Med. 1991] Prediction of radionuclide bone imaging findings by Gleason histologic grading of prostate carcinoma. Shih WJ, Mitchell B, Wierzbinski B, Magocum S, Ryo UY. Clin Nucl Med. 1991 Oct; 16(10):763-6. Review [Nuclear medicine diagnosis and therapy in urology. Diagnosis of bone metastases]. [Urologe A. 1993] Review [Nuclear medicine diagnosis and therapy in urology. Diagnosis of bone metastases]. Hach A, Melchior SW, Andreas J, Piepenburg R, Voges GE. Urologe A. 1993 Mar; 32(2):94-102. Review Nuclear medicine techniques for the diagnosis and therapy of prostate carcinoma. [Eur Urol. 2001] Review Nuclear medicine techniques for the diagnosis and therapy of prostate carcinoma. Oyen WJ, Witjes JA, Corstens FH. Eur Urol. 2001 Sep; 40(3):294-9. See reviews... See all... Related information Related Citations Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.Compound (MeSH Keyword) PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.Substance (MeSH Keyword) PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Salonia, A., Gallina, A., Camerota, T., Picchio, M., Freschi, M., Dapozzo, L., et al. (2006). Bone metastases are infrequent in patients with newly diagnosed prostate cancer: analysis of their clinical and pathologic features. UROLOGY, 68(2), 362-366 [10.1016/j.urology.2006.02.009].
Bone metastases are infrequent in patients with newly diagnosed prostate cancer: analysis of their clinical and pathologic features
DaPozzo, LF;FAZIO, FERRUCCIO;
2006
Abstract
OBJECTIVES: To investigate the clinical and pathologic characteristics of patients with bone metastases identified at the time of newly diagnosed prostate carcinoma at biopsy. METHODS: From November 2002 to May 2004, 1587 consecutive patients had a pathologic diagnosis of prostate cancer and underwent conventional technetium-99m methylene diphosphonate scintigraphy of the entire body. The clinical and pathologic features of those patients with positive bone scan findings (group 1) were compared with those of a subcohort of 372 patients with negative bone scan findings performed at the same nuclear medicine department (group 2). RESULTS: A retrospective complete data collection was available for 1242 of 1587 patients. Bone metastases were found in 31 patients (2.5%). As expected, patients with skeletal metastases had a significantly greater mean serum total prostate-specific antigen level, and a Gleason sum of 8 or 9 was significantly more frequent in the pathologic findings of these subjects. Group 1 patients had a significantly greater prevalence of previous nonprostate primary neoplasms (chi-square 12.74, df = 1, P = 0.0004) and reported a greater prevalence of current use of H2 blockers for the treatment and prevention of gastroesophageal reflux disorders (chi-square 37.52, df = 1, P < 0.0001) than did group 2 patients. CONCLUSIONS: Our data have confirmed that bone metastases are more frequent in patients with high prostate-specific antigen levels and poorly differentiated tumors at biopsy regardless of the patient's age. A history of previous nonprostate primary neoplasms and the use of H2 blockers seemed to be more prevalent in those patients with bone metastases at diagnosis. PMID:16904453[PubMed - indexed for MEDLINE] MeSH Terms, SubstancesMeSH TermsAgedBone Neoplasms/radionuclide imaging*Bone Neoplasms/secondary*HumansMaleProstatic Neoplasms/pathology*Radiopharmaceuticals/diagnostic useRetrospective StudiesTechnetium Tc 99m Medronate/diagnostic useSubstancesRadiopharmaceuticalsTechnetium Tc 99m Medronate LinkOut - more resourcesFull Text SourcesElsevier ScienceEBSCOMD ConsultOhioLINK Electronic Journal CenterSwets Information ServicesOther Literature SourcesLabome Researcher Resource - ExactAntigen/LabomeMedicalProstate Cancer - MedlinePlus Health InformationBone Cancer - MedlinePlus Health Information • Supplemental Content Related citations [Comparison of serum prostate specific antigen levels and bone scintigraphy in patients with prostate carcinoma]. [Medicina (Kaunas). 2003] [Comparison of serum prostate specific antigen levels and bone scintigraphy in patients with prostate carcinoma]. Bielickaite J, Zadeikaite R, Jurkiene N, Kiudelis J, Kuprionis G. Medicina (Kaunas). 2003; 39(9):867-71. The relationship between the serum prostate specific antigen and whole body scintigraphy in prostate cancer patients after prostatectomy. [Med Arh. 2006] The relationship between the serum prostate specific antigen and whole body scintigraphy in prostate cancer patients after prostatectomy. Begic A, Kucukalic-Selimovic E, Obralic N, Duric O, Lacevic N, Begovic-Hadzimuratovic S, Skopljak A, Dzubur-Aganovic M. Med Arh. 2006; 60(1):54-5. Prediction of radionuclide bone imaging findings by Gleason histologic grading of prostate carcinoma. [Clin Nucl Med. 1991] Prediction of radionuclide bone imaging findings by Gleason histologic grading of prostate carcinoma. Shih WJ, Mitchell B, Wierzbinski B, Magocum S, Ryo UY. Clin Nucl Med. 1991 Oct; 16(10):763-6. Review [Nuclear medicine diagnosis and therapy in urology. Diagnosis of bone metastases]. [Urologe A. 1993] Review [Nuclear medicine diagnosis and therapy in urology. Diagnosis of bone metastases]. Hach A, Melchior SW, Andreas J, Piepenburg R, Voges GE. Urologe A. 1993 Mar; 32(2):94-102. Review Nuclear medicine techniques for the diagnosis and therapy of prostate carcinoma. [Eur Urol. 2001] Review Nuclear medicine techniques for the diagnosis and therapy of prostate carcinoma. Oyen WJ, Witjes JA, Corstens FH. Eur Urol. 2001 Sep; 40(3):294-9. See reviews... See all... Related information Related Citations Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.Compound (MeSH Keyword) PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.Substance (MeSH Keyword) PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
